2025 Global Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report
Description
The 2025 Global Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Artificial Intelligence (AI) in Drug Discovery Market include Google DeepMind (and its sister company Isomorphic Labs), IBM Watson Health, BenevolentAI, and Atomwise. Google DeepMind is renowned for its AlphaFold AI system, which revolutionizes protein structure prediction, significantly enhancing drug candidate identification. Its sister company, Isomorphic Labs, uses cutting-edge AI techniques to tackle complex biological problems and has high-profile collaborations with Eli Lilly and Novartis. IBM Watson Health utilizes natural language processing and machine learning to mine scientific literature and identify drug targets, aiming to accelerate and optimize drug discovery. BenevolentAI combines AI with scientific expertise and wet-lab facilities to develop new medicines for complex diseases, emphasizing increased clinical success probability. Atomwise leverages structure-based deep learning via its AtomNet™ platform to predict drug-target interactions, facilitating efficient drug screening and discovery across therapeutic areas like infectious diseases and cancer.
These companies lead a dynamic and fast-growing market projected to reach billions in value by 2030, driven by AI's ability to reduce drug discovery timelines and costs. Partnerships with pharmaceutical giants, integrations of cloud computing, and advancements in machine learning, deep learning, and natural language processing are common strategies enabling these firms to maintain their competitive edge. For example, Exscientia’s collaboration with AWS exemplifies leveraging cloud AI for end-to-end discovery automation. Meanwhile, BenevolentAI and IBM Watson focus on integrating AI-driven target identification with drug optimization and clinical development. The transformative impact of AI in drug discovery underscores these firms' significance as pioneers advancing the pharmaceutical industry into a more efficient and precise future.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Artificial Intelligence (AI) in Drug Discovery Market include Google DeepMind (and its sister company Isomorphic Labs), IBM Watson Health, BenevolentAI, and Atomwise. Google DeepMind is renowned for its AlphaFold AI system, which revolutionizes protein structure prediction, significantly enhancing drug candidate identification. Its sister company, Isomorphic Labs, uses cutting-edge AI techniques to tackle complex biological problems and has high-profile collaborations with Eli Lilly and Novartis. IBM Watson Health utilizes natural language processing and machine learning to mine scientific literature and identify drug targets, aiming to accelerate and optimize drug discovery. BenevolentAI combines AI with scientific expertise and wet-lab facilities to develop new medicines for complex diseases, emphasizing increased clinical success probability. Atomwise leverages structure-based deep learning via its AtomNet™ platform to predict drug-target interactions, facilitating efficient drug screening and discovery across therapeutic areas like infectious diseases and cancer.
These companies lead a dynamic and fast-growing market projected to reach billions in value by 2030, driven by AI's ability to reduce drug discovery timelines and costs. Partnerships with pharmaceutical giants, integrations of cloud computing, and advancements in machine learning, deep learning, and natural language processing are common strategies enabling these firms to maintain their competitive edge. For example, Exscientia’s collaboration with AWS exemplifies leveraging cloud AI for end-to-end discovery automation. Meanwhile, BenevolentAI and IBM Watson focus on integrating AI-driven target identification with drug optimization and clinical development. The transformative impact of AI in drug discovery underscores these firms' significance as pioneers advancing the pharmaceutical industry into a more efficient and precise future.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
